Eric Venker sold $1.2M of ROIV
President & Immunovant CEO at Roivant Sciences Ltd.. 100,000 shares at an average of $11.72, traded Aug 20, 2025, filed Aug 22, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.2M at market
- 0Share of holdings soldSold 5.7% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-25-032404, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 20, 2025 | FTax withholding Common Shares10b5-1 | -7,051 | $11.72 | $83k | 1,653,585 | Aug 22, 2025 |
| Aug 20, 2025 | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 1,753,585 | Aug 22, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.72 | $1.2M | 1,653,585 | Aug 22, 2025 |
| Aug 20, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 8,038,897 | Aug 22, 2025 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 45Moderate | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $29M 1,330,868 shares | -7% | |
| 67Notable | Roivant Sciences Ltd. | Richard Pulik CFO | $9.1M 406,731 shares | -63% | |
| 55Moderate | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $6.2M 275,000 shares | -15% | |
| 40Moderate | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $620k 26,831 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.